HighPoint Advisor Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

HighPoint Advisor Group’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,250	Closed	-$4	–	701
2024 Q4	$4	Hold	22,250	–	–	﹤0.01%	695
2024 Q3	$60	Buy	+22,250	New	+$60	﹤0.01%	692
2024 Q2	–	Sell	-22,250	Closed	–	–	647
2024 Q1	$0	Hold	22,250	–	–	﹤0.01%	671
2023 Q4	$0	Buy	+22,250	New	–	﹤0.01%	652
2022 Q2	$51K	Buy	+20,035	New	+$34.6K	0.01%	515
2021 Q3	$156K	Sell	20,435 -500	-2%	-$4.24K	0.02%	525
2021 Q2	$203K	Sell	20,935 -3,900	-16%	-$31.1K	0.02%	505
2021 Q1	$187K	Buy	24,835 +250	+1%	+$2.64K	0.02%	465
2020 Q4	$396K	Buy	+24,585	New	+$197K	0.05%	300

Other funds holding SRNE

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

HighPoint Advisor Group's SRNE Position: Q1 2025 in Review

HighPoint Advisor Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2025, closing a stake of 22,250 shares — an estimated $4 sold.

HighPoint Advisor Group first reported a position in SRNE in Q4 2020 and held it in 9 quarters. The position peaked at $396K in Q4 2020. 4 funds tracked by Wall St. Rank hold SRNE as of Q1 2025.

HighPoint Advisor Group reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
HighPoint Advisor Group sold 22,250 Sorrento Therapeutics, Inc. shares in Q1 2025, an estimated $4.
HighPoint Advisor Group first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 9 quarters.
HighPoint Advisor Group's Sorrento Therapeutics, Inc. position peaked at $396K in Q4 2020.
4 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2025.

Based on HighPoint Advisor Group's 13F filing for Q1 2025, filed 5 May 2025.